Archives — January 2012 back to current month (2)

Hepatitis C and Orphan Diseases Driving Big Biotech Potential: Geoff Meacham (01/31/2012)

It may seem counterintuitive that rare diseases might actually be biotech growth drivers, but Senior Analyst and Managing Director Geoff Meacham of JPMorgan Chase makes just that case. In this exclusive interview with The Life Sciences Report, Meacham lays out his premise that hepatitis C and orphan disease drugs can cure the woes of growth-starved investors.

more>

Driving Value for Pharma and Biotech Companies: Insights from Biotech Showcase 2012 (01/20/2012)

The 2012 Biotech Showcase investor conference in San Francisco drew a record number of life science interests from all over the world.

more>

More Archives

2017Jul Jun May Apr Mar Feb Jan

2016Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec

2015Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec

2014Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec

2013Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec

2012Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec

Get Our Streetwise Reports Life Sciences Report Newsletter Free

A valid email address is required to subscribe